FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1514453574> ?p ?o ?g. }

• W1514453574 abstract "OBJECTIVE: To examine the incidence of ATEs in AVAglio.BACKGROUND: A significant PFS improvement (co-primary endpoint) was achieved in patients treated with BEV+RT/TMZ versus placebo (Plb+RT/TMZ). AVAglio safety data are presented, with a focus on ATEs.DESIGN/METHODS: Patients (蠅18 years/histologically confirmed glioblastoma) received BEV+RT/TMZ or Plb+RT/TMZ (6wks). After a 28-day break, patients received BEV+TMZ or Plb+TMZ (x6), then BEV or Plb until progression/unacceptable toxicity. Adverse events (AEs) of special interest for BEV were predefined. Statistical analyses: exploratory, non-protocol specified.RESULTS: Safety population: n=461 BEV+RT/TMZ; n=450 Plb+RT/TMZ. BEV or Plb administrations: median 19.0 (range 1-59) vs 12 (range 1-63) infusions, respectively. For BEV+RT/TMZ versus Plb+RT/TMZ, respectively: grade 蠅3 AEs were 66.8% vs 51.3%; grade 蠅3 AEs of special interest for BEV were 32.5% vs 15.8%; ATEs (any grade) were 5.9% (27/461 patients) vs 1.6% (7/450); grade 蠅3 ATEs were 4.8% (22/461) and 1.3% (6/450). Of the latter, 19/22 (86.4%) and 3/6 (50%) patients had 蠅1 co-morbidity risk factor. Two fatal ATEs occurred: myocardial infarction (BEV+RT/TMZ); cerebrovascular accident (Plb+RT/TMZ). ATE event rates were similar between arms until approximately 12 months, after which the rate in the BEV+RT/TMZ arm increased. Grade 蠅3 ATEs resolved in 15/22 (68%; BEV+RT/TMZ; 10/15 with sequelae) and 3/6 (50%; Plb+RT/TMZ; 2/3 with sequelae) patients. Most ATEs were classified as stroke (19/27 BEV+RT/TMZ; 6/7 Plb+RT/TMZ). Eleven strokes occurred in patients <65 years in the BEV+RT/TMZ arm (seven following 1.2-1.7 years of treatment without progression), nine of which resolved. Nine grade 蠅3 ATEs (BEV+RT/TMZ) occurred in patients 蠅65 years (vs 0 with Plb+RT/TMZ), five with a history of hypertension. In patients who experienced ATEs, median OS was 25.0 (BEV+RT/TMZ; n=27) and 11.2 months (Plb+RT/TMZ; n=7).CONCLUSION: More ATEs were reported in the BEV+RT/TMZ versus Plb+RT/TMZ arm. ATEs in the BEV+RT/TMZ arm tended to occur late in the study and may be related to prolonged treatment duration/co-morbidities, however the majority resolved (two-thirds with sequelae). Study supported by: F. Hoffmann-La Roche Ltd Disclosure: Dr. Mason has received personal compensation for activities with Roche Diagnostics Corporation. Dr. Cloughsey has received personal compensation for activities with F. Hoffman-La Roche, Genentech Inc., Merck & Co. Inc., Merck & Co. Inc., Serono Inc., Celgene, Tocagen, Apogenix, and Newgen. Dr. Wick has received personal compensation for activities with Roche Diagnostics Corp., Merck Sharp & Dohme Ltd. Dr. Wick has received personal compensation in an editorial capacity for CNS Oncology. Dr. Wick has received research support from Boehringer Ingelheim Pharmaceuticals Inc., Apogenix, and Merck Sharp & Dohme Ltd. Dr. Henrisksson has received personal compensation for activities with F. Hoffmann-La Roche. Dr. Saran has received personal compensation for activities with Roche Diagnostics Corp. Dr. Nishikawa has received personal compensation for activities with F. Hoffman–La Roche. Dr. Dhar has received personal compensation for activities with Genentech Inc. as an employee. Dr. Revil has received personal compensation for activities with F. Hoffmann-La Roche as an employee. Dr. Garcia has received personal compensation for activities with F. Hoffmann-La Roche Ltd. as an employee. Dr. Chinot has received personal compensation for activities with F. Hoffmann-La Roche, AstraZeneca Pharmaceuticals, and Merck Sharp & Dohme Ltd. Dr. Chinot has received research support from F. Hoffmann-La Roche and Schering-Plough Corporation." @default.
• W1514453574 created "2016-06-24" @default.
• W1514453574 creator A5001810357 @default.
• W1514453574 creator A5006549117 @default.
• W1514453574 creator A5012219489 @default.
• W1514453574 creator A5034105859 @default.
• W1514453574 creator A5042329751 @default.
• W1514453574 creator A5044767725 @default.
• W1514453574 creator A5058554538 @default.
• W1514453574 creator A5063511816 @default.
• W1514453574 creator A5080482957 @default.
• W1514453574 creator A5088507451 @default.
• W1514453574 date "2014-04-08" @default.
• W1514453574 modified "2023-09-26" @default.
• W1514453574 title "Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003)" @default.
• W1514453574 hasPublicationYear "2014" @default.
• W1514453574 type Work @default.
• W1514453574 sameAs 1514453574 @default.
• W1514453574 citedByCount "0" @default.
• W1514453574 crossrefType "journal-article" @default.
• W1514453574 hasAuthorship W1514453574A5001810357 @default.
• W1514453574 hasAuthorship W1514453574A5006549117 @default.
• W1514453574 hasAuthorship W1514453574A5012219489 @default.
• W1514453574 hasAuthorship W1514453574A5034105859 @default.
• W1514453574 hasAuthorship W1514453574A5042329751 @default.
• W1514453574 hasAuthorship W1514453574A5044767725 @default.
• W1514453574 hasAuthorship W1514453574A5058554538 @default.
• W1514453574 hasAuthorship W1514453574A5063511816 @default.
• W1514453574 hasAuthorship W1514453574A5080482957 @default.
• W1514453574 hasAuthorship W1514453574A5088507451 @default.
• W1514453574 hasConcept C126322002 @default.
• W1514453574 hasConcept C142724271 @default.
• W1514453574 hasConcept C143998085 @default.
• W1514453574 hasConcept C197934379 @default.
• W1514453574 hasConcept C203092338 @default.
• W1514453574 hasConcept C204787440 @default.
• W1514453574 hasConcept C27081682 @default.
• W1514453574 hasConcept C2776694085 @default.
• W1514453574 hasConcept C2777389519 @default.
• W1514453574 hasConcept C2777802072 @default.
• W1514453574 hasConcept C2908647359 @default.
• W1514453574 hasConcept C31760486 @default.
• W1514453574 hasConcept C509974204 @default.
• W1514453574 hasConcept C535046627 @default.
• W1514453574 hasConcept C71924100 @default.
• W1514453574 hasConcept C99454951 @default.
• W1514453574 hasConceptScore W1514453574C126322002 @default.
• W1514453574 hasConceptScore W1514453574C142724271 @default.
• W1514453574 hasConceptScore W1514453574C143998085 @default.
• W1514453574 hasConceptScore W1514453574C197934379 @default.
• W1514453574 hasConceptScore W1514453574C203092338 @default.
• W1514453574 hasConceptScore W1514453574C204787440 @default.
• W1514453574 hasConceptScore W1514453574C27081682 @default.
• W1514453574 hasConceptScore W1514453574C2776694085 @default.
• W1514453574 hasConceptScore W1514453574C2777389519 @default.
• W1514453574 hasConceptScore W1514453574C2777802072 @default.
• W1514453574 hasConceptScore W1514453574C2908647359 @default.
• W1514453574 hasConceptScore W1514453574C31760486 @default.
• W1514453574 hasConceptScore W1514453574C509974204 @default.
• W1514453574 hasConceptScore W1514453574C535046627 @default.
• W1514453574 hasConceptScore W1514453574C71924100 @default.
• W1514453574 hasConceptScore W1514453574C99454951 @default.
• W1514453574 hasOpenAccess W1514453574 @default.
• W1514453574 hasRelatedWork W1583454600 @default.
• W1514453574 hasRelatedWork W1594175490 @default.
• W1514453574 hasRelatedWork W2039289142 @default.
• W1514453574 hasRelatedWork W2089699323 @default.
• W1514453574 hasRelatedWork W2146357043 @default.
• W1514453574 hasRelatedWork W2167652138 @default.
• W1514453574 hasRelatedWork W2337172610 @default.
• W1514453574 hasRelatedWork W2338792363 @default.
• W1514453574 hasRelatedWork W2341505902 @default.
• W1514453574 hasRelatedWork W2406966535 @default.
• W1514453574 hasRelatedWork W2596870213 @default.
• W1514453574 hasRelatedWork W2736712994 @default.
• W1514453574 hasRelatedWork W2944881201 @default.
• W1514453574 hasRelatedWork W2969591537 @default.
• W1514453574 hasRelatedWork W2999435318 @default.
• W1514453574 hasRelatedWork W2999619211 @default.
• W1514453574 hasRelatedWork W2999681099 @default.
• W1514453574 hasRelatedWork W2999704106 @default.
• W1514453574 hasRelatedWork W3000322062 @default.
• W1514453574 hasRelatedWork W3184819313 @default.
• W1514453574 hasVolume "82" @default.
• W1514453574 isParatext "false" @default.
• W1514453574 isRetracted "false" @default.
• W1514453574 magId "1514453574" @default.
• W1514453574 workType "article" @default.